Figure 3 of Xu, Mol Vis 2010; 16:1982-1995.

Figure 3. Inhibition effects of H-RN and H-FT on endothelial cell differentiation into capillary structures. Starved RF/6A cells were pre-incubated with different concentrations of bevacizumab, H-RN, and H-FT for 30 min before 100 ng/ml vascular endothelial growth factor (VEGF) was added in peptides treated and VEGF groups, and then cells were seeded into Matrigel-coated wells. A-F: Representative photographs of anti-tube formation activity of bevacizumab, H-RN, H-FT, and scrambled peptide: A, no-VEGF; B, 100 ng/ml VEGF; C, 100 ng/ml VEGF +2.5 mg/ml bevacizumab; D, 100 ng/ml VEGF +1 mM H-RN; E, 100 ng/ml VEGF +100 nM H-FT; F, 100 ng/ml VEGF +1 mM scrambled peptide. VEGF at 100 ng/ml strongly stimulated endothelium tube formation. Bevacizumab and H-RN potently inhibited VEGF-stimulated RF/6A cell tube formation on growth factor-reduced Matrigel™. H-FT and scrambled peptide did not inhibit RF/6A cell tube formation effectively (magnification ×200). G: Quantitative analysis of tube formation under the different experimental conditions using Image Program Plus software. The values are mean tube lengths from three repeated experiments (** p<0.01, each condition versus control).